Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) just unveiled an announcement.
Chimeric Therapeutics Ltd. has called an extraordinary general meeting for 17 April 2026, to be held in Carlton, Victoria, and simultaneously via an online platform, allowing shareholders to participate either in person or virtually. The company is encouraging investors who cannot attend online to lodge proxy forms in advance and is providing phone support and an online meeting guide to facilitate questions, attendance and voting, underscoring its focus on broad shareholder engagement and accessible governance.
Shareholders will be able to log in to the webcast using their voting access code and registered postcode or country code, ensuring secure verification for both Australian and overseas holders. By offering a hybrid meeting format and clear voting instructions, Chimeric aims to maximize participation in corporate decision-making, which may help strengthen investor relations and demonstrate responsiveness to a geographically dispersed shareholder base.
The most recent analyst rating on (AU:CHM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is a biotechnology company focused on developing cell-based therapies, operating in the life sciences sector and listed in Australia. The company’s activities center on advanced therapeutic platforms targeting unmet medical needs, with a shareholder base that includes both domestic and overseas investors.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.84M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.